Pharma giant Amgen Inc. made two big investment offers in recent months – $13.4 billion for Celgene Corp.’s Otezla and $2.7 billion for a 20.5 percent stake in Chinese cancer biotech BeiGene.

Both deals position the Thousand Oaks company for future growth overseas, while also providing near-term cash flow.

Read the full story in the Nov. 11 issue of the San Fernando Valley Business Journal.